March 2020 Special Edition
Volume 6, Issue 4.1
This supplement takes a look at the future of chemoimmunotherapy for chronic lymphocytic leukemia, the latest FDA approvals for the treatment of lymphoid and plasma cell malignancies, and more.
Table of Contents
March 2020 Special Edition
The Year in FDA Approvals
In the past year, the FDA approved a record-breaking number of drugs, several of which were indicated for the treatment of lymphoid and plasma...
March 2020 Special Edition
Extinguishing Smoldering Myeloma?
For patients with smoldering myeloma – a precursor stage of multiple myeloma (MM) – the standard approach for years has been “watch and wait,”...
Is Chemoimmunotherapy for Upfront CLL on Life Support?
For years, standard of care first-line treatment for chronic lymphocytic leukemia (CLL) included the FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy regimen. However, the past decade...
March 2020 Special Edition
Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma
Treatment with the investigational anti-CD38 monoclonal antibody isatuximab plus the combination of pomalidomide and low-dose dexamethasone (Pd) led to a median progression-free survival (PFS)...
Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting
According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...
Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL
According to results from the Children’s Oncology Group AALL0331 trial, pediatric patients with standard-risk B-cell acute lymphocytic leukemia (ALL) had a high rate of...
March 2020 Special Edition
Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL
The availability of B-cell receptor inhibitors (BCRis) and other novel agents for the treatment of chronic lymphocytic leukemia (CLL) has reshaped the treatment paradigm...
Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL
Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR) after treatment with a combination of venetoclax and navitoclax,...
Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma
Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) followed by autologous transplant and Dara-KRd consolidation guided by measurable residual disease (MRD) leads to...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding the antibiotic clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd)...
Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?
Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of patients with limited-stage diffuse large B-cell lymphoma (DLBCL) maintained...
DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma
In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and pegasparaginase (DDGP) improved survival compared...
Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL
Approximately 93% of patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and del17p responded to treatment with the next-generation Bruton tyrosine kinase (BTK)...
